Back to Search Start Over

Zero Mortality in Living-Donor Liver Transplantation for Primary Biliary Cholangitis in Patients With a Meld Score of <20.

Authors :
Yanagaki M
Onda S
Furukawa K
Taniai T
Haruki K
Akaoka M
Shirai Y
Matsumoto M
Gocho T
Uwagawa T
Ikegami T
Source :
Transplantation proceedings [Transplant Proc] 2023 May; Vol. 55 (4), pp. 898-900. Date of Electronic Publication: 2023 Apr 22.
Publication Year :
2023

Abstract

Background: Although primary biliary cholangitis (PBC) is considered a good indication for living-donor liver transplantation (LDLT), the postoperative results are not well known.&lt;br /&gt;Methods: At Jikei University Hospital, 14 patients with PBC underwent LDLT from February 2007 to June 2022. We consider PBC with a Model for End-Stage Liver Disease (MELD) score of &lt;20 to indicate LDLT. We performed a retrospective analysis of the patients&#39; clinical records.&lt;br /&gt;Results: The patients&#39; median age was 53 years, and 12 of the 14 patients were female. A right graft was used in 5 patients, and 3 ABO-incompatible transplants were performed. The living donors were children in 6 cases, partners in 4 cases, and siblings in 4 cases. The preoperative MELD scores ranged from 11 to 19 (median, 15). The graft-to-recipient weight ratio ranged from 0.8 to 1.1 (median, 1.0). The median operative time for donors and recipients was 481 and 712 minutes, respectively. The median operative blood loss of donors and recipients was 173 and 1,800 mL, respectively. The median postoperative hospital stay of donors and recipients was 10 and 28 days, respectively. All recipients recovered satisfactorily and remained well during a median follow-up of 7.3 years. Three patients underwent a liver biopsy after LDLT because of acute cellular rejection without histologic findings of PBC recurrence.&lt;br /&gt;Conclusions: Living-donor liver transplantation provides satisfactory long-term survival for patients with PBC with a graft-to-recipient weight ratio of &gt;0.7 and MELD score of &lt;20 without hepatocellular damage and only portal vein hypertension.&lt;br /&gt;Competing Interests: DISCLOSURES The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.&lt;br /&gt; (Copyright &#169; 2023 Elsevier Inc. All rights reserved.)

Details

Language :
English
ISSN :
1873-2623
Volume :
55
Issue :
4
Database :
MEDLINE
Journal :
Transplantation proceedings
Publication Type :
Academic Journal
Accession number :
37095011
Full Text :
https://doi.org/10.1016/j.transproceed.2023.03.046